Business Standard

Novavax signs Covid-19 vaccine supply deal with India's Serum Institute

The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal

covid, coronavirus, vaccine, drug, pharma
Premium

On Tuesday, Novavax reported that its experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial

Reuters
Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its Covid-19 vaccine candidate.
The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the "Pandemic Period" in all countries other than those designated by the World Bank as upper-middle or high-income countries.

The deal was signed on July 30, according to an SEC filing by

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in